Share on StockTwits

ZELTIQ Aesthetics (NASDAQ:ZLTQ) posted its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.05, Analyst Ratings.Net reports. The company had revenue of $31.00 million for the quarter, compared to the consensus estimate of $27.54 million.

Shares of ZELTIQ Aesthetics (NASDAQ:ZLTQ) traded up 0.42% on Tuesday, hitting $19.27. The stock had a trading volume of 531,870 shares. ZELTIQ Aesthetics has a 1-year low of $3.78 and a 1-year high of $24.79. The stock’s 50-day moving average is $18.5 and its 200-day moving average is $17.61. The company’s market cap is $717.0 million.

In other ZELTIQ Aesthetics news, CEO Mark Foley sold 7,123 shares of ZELTIQ Aesthetics stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $18.05, for a total value of $128,570.15. Following the sale, the chief executive officer now directly owns 705,638 shares in the company, valued at approximately $12,736,766. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on ZLTQ shares. Analysts at Stifel Nicolaus initiated coverage on shares of ZELTIQ Aesthetics in a research note on Wednesday, March 19th. They set a “buy” rating and a $28.00 price target on the stock. Analysts at Leerink Swann initiated coverage on shares of ZELTIQ Aesthetics in a research note on Friday, February 21st. They set an “outperform” rating and a $26.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $23.11.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.